Chasman, Daniel I.
Hyde, Craig L.
Giulianini, Franco
Danning, Rebecca D.
Wang, Ellen Q.
Hickling, Timothy
Ridker, Paul M
Loomis, A. Katrina
Funding for this research was provided by:
Pfizer
Article History
Received: 3 December 2021
Accepted: 14 February 2022
First Online: 11 March 2022
Competing interests
: C. Hyde, E. Wang, and A. K. Loomis are employees of Pfizer, Inc. T. Hickling was an employee of Pfizer, Inc. during the design and implementation of the study. P. Ridker has received research grant support from Novartis, Kowa, Amarin, Pfizer, and the NHLBI; and has served as a consultant to Corvidia, Novartis, Flame, Agepha, Inflazome, AstraZeneca, Jannsen, Civi Biopharm, SOCAR, Novo Nordisk, Uptton, and Omeicos, and Boehringer-Ingelheim. D. Chasman has received funding support from Pfizer Inc. related to the genetics of bococizumab treatment. R. Danning and F. Giulianini have no disclosures.